Condition
Type 2 DM
ClinicalTrials.gov condition label
Clinical trials
9 shownGlycemic Control With Triple Pathway Approach Through Empagliflozin, Linagliptin and Metformin CombinationNCT06862739 · 2025-10-30
RECRUITINGImplementation pRogram to Improve Screening and Management for CKD in Diabetes (IRIS-CKD) (Program 2)NCT06906640 · 2025-10-28
RECRUITINGImplementation pRogram to Improve Screening and Management for CKD in Diabetes (Program 1) (IRIS-CKD)NCT06906627 · 2025-10-28
RECRUITINGUrinary Proteomics to Guide Early Intervention to Prevent Complications in Type 2 Diabetes - a Feasibility StudyNCT06954090 · 2025-11-20
ENROLLING_BY_INVITATIONEmbecta AID System in Adults With Type 2 DiabetesNCT06692153 · 2025-01-01
WITHDRAWNTelehealth-Based Chronic Disease Management for Type 2 DiabetesNCT06719050 · 2024-12-18
NOT_YET_RECRUITINGSafety and Efficacy Assessment of Unani Formulation 'Dolabi' in Management of Diabetes Mellitus Type IINCT06841497 · 2024-07-04
ACTIVE_NOT_RECRUITINGCarbohydrate Quality and Its Impact on Sleep and Depression in Type 2 DiabetesNCT06666205 · 2023-04-01
COMPLETEDPrevention of Coronary Heart Disease in Morbidly Obese PatientsNCT00626964 · 2008-02-01
ACTIVE_NOT_RECRUITINGCommon interventions
(IRIS-CKD Management Program): EducationOTHER1(IRIS-CKD Management Program): GDMTOTHER1(IRIS-CKD Screening Program): Home KitOTHER1(IRIS-CKD Screening Program): Standard Lab OrderOTHER1An AID System.DEVICE1Bariatric SurgeryPROCEDURE1Conservative Treatment:BEHAVIORAL1Dapagliflozin (DAPA)DRUG1DolabiOTHER1Empagliflozin+Linagliptin+MetforminCOMBINATION_PRODUCT1Finerenone Oral TabletDRUG1Semaglutide, 1.34 mg/mLDRUG1Standard of Care (SC)OTHER1
Leading sponsors
Trial status mix
RECRUITING3
ACTIVE_NOT_RECRUITING2
COMPLETED1
ENROLLING_BY_INVITATION1
NOT_YET_RECRUITING1
WITHDRAWN1
Phase mix
NA4
PHASE42
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.